biologic

Asparlas

calaspargase pegol-mknl

Loss of exclusivityDecember 2030projected — 12-year biologic exclusivity estimate
CompanyServier Pharmaceuticals LLC

Drug detail

Brand nameAsparlas
Active ingredientcalaspargase pegol-mknl
Strength3,750UNITS/5ML (750UNITS/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalDecember 2018
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Asparlas patent cliff — loss of exclusivity December 2030 | CliffBio